Ovation and PD Theranostics have completed a merger to advance their capabilities in multiomic data and biobank management, creating a leading industry entity. With more than 1.6 million biospecimens from 600,000+ patients primarily in the U.S., the expanded biobank will see 200,000+ new samples monthly. The combined entity will leverage deep expertise in genomics, bioinformatics, disease pathogenesis, and pathology, providing robust datasets for disease research. The merger aims to accelerate the generation of multiomic data linking DNA sequencing with cellular footprints and pathology imaging. This will enhance drug discovery, clinical trials, and patient treatment strategies. Ovation’s new platform, incorporating PDTx’s technology, will create the world’s largest commercially available genomic dataset, facilitating high-resolution molecular analysis and data commercialization. Collaborations and exclusive licenses with Massachusetts General Hospital further support the scientific ambitions of this amalgamation. Lucius Partners, which has been instrumental in the merger, anticipates significant improvements in healthcare solutions and shareholder value.
Biotechnology, Healthcare, Information Technology,United States, Global
https://mergersacquisitions.einnews.com/article/741027346/wXr3wQRPwQ0OM58z?ref=rss&ecode=Q1vNcweEggLWKz7L